A Phase 1b Study of Humanized Ks-Interleukin-2 (Huks-Il2) Immunocytokine with Cyclophosphamide in Patients with Epcam-Positive Advanced Solid Tumors

Authors

Joseph P. Connor
Mihaela C. Cristea
Nancy L. Lewis
Lionel D. Lewis

Document Type

Article

Publication Date

2013

Publication Title

BMC Cancer

Department

Geisel School of Medicine

Abstract

BackgroundHumanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent.MethodsPhase 1b study in patients with EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) and safety profile of huKS-IL2 in combination with low-dose cyclophosphamide. Treatment consisted of cyclophosphamide (300mg/m2 on day 1), and escalating doses of h

DOI

10.1186/1471-2407-13-20

Comments

Connor, Joseph||Cristea, Mihaela||Lewis, Nancy||Lewis, Lionel||Komarnitsky, Philip||Mattiacci, Maria||Felder, Mildred||Stewart, Sarah||Harter, Josephine||Henslee-Downey, Jean||Kramer, Daniel||Neugebauer, Roland||Stupp, Roger

Original Citation

Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, Kramer D, Neugebauer R, Stupp R. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 2013 Jan 15;13:20. doi: 10.1186/1471-2407-13-20. PMID: 23320927; PMCID: PMC3600662.

Dartmouth Digital Commons Citation

Connor, Joseph P.; Cristea, Mihaela C.; Lewis, Nancy L.; and Lewis, Lionel D., "A Phase 1b Study of Humanized Ks-Interleukin-2 (Huks-Il2) Immunocytokine with Cyclophosphamide in Patients with Epcam-Positive Advanced Solid Tumors" (2013). Dartmouth Scholarship. 2509.
https://digitalcommons.dartmouth.edu/facoa/2509